受托管理事务报告 （2024 年度） 股票简称：药石科技 股票代码：300725 转债简称：药石转债 转债代码：123145 南京药石科技股份有限公司 向不特定对象发行可转换公司债券 债券受托管理人 （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 二〇二五年六月 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"管理办法"）、《南京药 石科技股份有限公司与华泰联合证券有限责任公司关于南京药石科技股份有限 公司向不特定对象发行可转换公司债券之债券受托管理协议》（以下简称"受托 管理协议"）、《南京药石科技股份有限公司向不特定对象发行可转换公司债券并 在创业板上市募集说明书》（以下简称"募集说明书"）、《南京药石科技股份有限 公司 2024 年年度报告》等相关公开信息披露文件、第三方中介机构出具的专业 意见等，由本期可转换公司债券受托管理人华泰联合证券有限责任公司（以下简 称"华泰联合证券"）编制。华泰联合证券对本报告中所包含的从上述文件中引 述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和 完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或 ...

华福证券认为，港股创新药（含Pharma）为医药板块中最强势的板块，其次为创新药产业链CRO板 块，创新药已成为市场认可的主线之一，个股方面从主流一二线标的，行情亦在向有创新药布局或BD 预期的中药或仿制药标的扩展。短期创新药建议积极拥抱龙头和一线标的。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） 消息面上，据央视新闻，6月13日国务院常务会议召开研究优化药品和耗材集采有关举措。会议指出， 要加强药品和耗材集采政策评估，总结经验、补齐短板，推动集采工作规范化制度化常态化开展。要更 好促进"三医"协同发展和治理，完善公立医院补偿机制，支持医药企业提高创新能力，更好满足群众多 元化就医用药需求。要加强对药品和耗材生产、流通、使用全链条质量监管，扎实推进仿制药质量和疗 效一致性评价，让人民群众用药放心安心。 东吴证券指出，创新药BD推动及优秀临床数据下，看好的医药子行业排序分别为：创新药>CXO>中药 >医疗器械>药店>医药商业等。具体标的选择思路：从成长性角度选股，主要集中创新药领域；从左侧 角度选股，主要集中在CXO、医疗器械。 6月16日，创新药概念小幅 ...

Group 1 - The CRO concept index rose by 3.41%, ranking 6th among concept sectors, with 59 stocks increasing in value [1] - Leading stocks in the CRO sector included Lianhua Technology and Hehua Co., which hit the daily limit, while Tianyu Co. and Haitai Bio saw significant gains of 19.72% and 13.18% respectively [1] - The stocks with the largest declines included *ST Shuangcheng, Fosun Pharma, and Kailai Ying, which fell by 3.08%, 0.39%, and 0.24% respectively [1] Group 2 - The CRO sector experienced a net inflow of 0.45 billion yuan, with 25 stocks receiving net inflows, and 14 stocks attracting over 10 million yuan [2] - Hehua Co. led the net inflow with 1.68 billion yuan, followed by Lianhua Technology and Haoyuan Pharmaceutical with net inflows of 834.83 million yuan and 749.80 million yuan respectively [2] - The top stocks by net inflow ratio included Hehua Co. at 28.79%, Haoyuan Pharmaceutical at 12.05%, and Nearshore Protein at 11.73% [3] Group 3 - The trading volume and turnover rates for leading stocks in the CRO sector were notable, with Hehua Co. achieving a turnover rate of 18.47% and Lianhua Technology at 13.17% [3] - Other significant stocks included Yaosheng Technology and Sichuan Shuangma, which also showed positive performance with gains of 5.21% and 5.29% respectively [3] - Stocks like Tianyu Co. and Ruizhizhi Pharmaceutical had substantial trading activity, with Tianyu Co. rising by 19.72% and Ruizhizhi Pharmaceutical by 13.15% [5]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于药石转债恢复转股的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示: | 证券代码：300725 | 证券简称：药石科技 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 恢复转股时间：2025年5月30日 | | 南京药石科技股份有限公司（以下简称"公司"）因实施2024年年度权益 分派方案，根据《南京药石科技股份有限公司向不特定对象发行可转换公司债 券创业板上市募集说明书》（以下简称"《募集说明书》"）及相关规定，公 司可转换公司债券（债券简称：药石转债，债券代码：123145）于2025年5月21 日起暂停转股。根据《募集说明书》及相关规定，"药石转债"将于本次权益 分派股权登记日后的第一个交易日，即2025年5月30日起恢复转股。敬请公司可 转换公司债券持有人留意。 特此公告。 南 ...

Group 1 - The pharmaceutical sector is experiencing renewed activity, particularly in CRO, innovative drugs, and medical services, with significant gains in related ETFs [1] - The Biopharmaceutical ETF (159859) rose by 1.7%, with trading volume exceeding 50 million yuan, while the Innovative Drug ETF Tianhong (517380) increased by 1.66%, with several constituent stocks rising over 5% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ) and is the largest product in its category, also offering a connecting fund [1] Group 2 - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago and online [2] - The innovative drug sector is highlighted as a key focus for the year, with attention on areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy, alongside domestic pharmaceutical consumption and medical aesthetics [2] - The innovative drug sector is expected to maintain its growth, supported by policy, global competitiveness, and improving fundamentals, with a potential recovery in demand anticipated by 2025 [2]

| 证券代码：300725 | 证券简称：药石科技 公告编号：2025-039 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 关于 2024 年度权益分派调整可转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、特别提示 1、债券代码：123145 债券简称：药石转债 2、调整前"药石转债"的转股价格为：33.89 元/股 3、调整后"药石转债"的转股价格为：33.61 元/股 4、本次权益分派期间，"药石转债"暂停转股 836,090股后，分配股份基数为198,893,879股，公司将按照现金分红总额固定不变 的原则对分配比例进行相应调整。具体调整如下：本次派息总额÷公司扣除回购 后总股本×10＝55,690,204.92÷198,893,879×10＝2.799995元（保留六位小数， 最后一位直接截取，不四舍五入），即每股现金股利为0.2799995元。由于保留六 位小数，最后一位直接截取，不四舍五入，按照最新每股现金股利及股本计算的 现金股利总额为55,690,18 ...

| 证券代码：300725 | 证券简称：药石科技 公告编号：2025-038 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示: 1、南京药石科技股份有限公司发行的可转换公司债券"药石转债"（债券 代码：123145）目前尚在转股期，"药石转债"已经申请自2025年5月21日至本 次权益分派股权登记日期间暂停转股，具体内容详见公司于2025年5月19日披露 的《关于实施权益分派期间药石转债暂停转股的提示性公告》（公告编号：2025- 036）。 民币现金（含税；扣税后，通过深股通持有股份的香港市场投资者、QFII、RQFII 以及持有首发前限售股的个人和证券投资基金每10股派2.519995元；持有首发后 限售股、股权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收， 本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额 【注】；持有首发后限售股、股权激励限售股及无限售流通股的证券 ...

Market Overview - The Shanghai Composite Index closed at 3348.37 points, above the annual line, with a decline of 0.94% [1] - The total trading volume of A-shares reached 1,182.564 billion yuan [1] Stocks Breaking Annual Line - A total of 31 A-shares have surpassed the annual line today, with notable stocks including: - Pruis (4.48% deviation) - Yingjie Electric (3.80% deviation) - Boying Special Welding (3.01% deviation) [1] - Stocks with smaller deviations just above the annual line include: - Shuangjian Co., Ltd. - Rhine Biology - Bull Group [1] Top Performers - The top three stocks with the highest deviation rates from the annual line are: 1. Pruis: 5.17% increase, 8.64% turnover rate, latest price 30.12 yuan 2. Yingjie Electric: 5.80% increase, 8.35% turnover rate, latest price 48.50 yuan 3. Boying Special Welding: 3.28% increase, 6.03% turnover rate, latest price 22.70 yuan [1] Additional Notable Stocks - Other notable stocks with significant performance include: - Fosa Technology: 3.03% increase, 8.32% turnover rate, latest price 32.31 yuan - Shandong Haihua: 5.57% increase, 6.80% turnover rate, latest price 5.88 yuan - Renfu Pharmaceutical: 3.06% increase, 2.53% turnover rate, latest price 20.88 yuan [1]

Market Overview - As of 13:59 today, the Shanghai Composite Index is at 3372.33 points, with a slight decline of -0.23% [1] - The total trading volume of A-shares today is 838.849 billion yuan [1] Stocks Breaking Annual Line - A total of 68 A-shares have surpassed their annual line today, with notable stocks including: - Puris (乖离率 6.48%) - Aisen Co., Ltd. (乖离率 5.81%) - Fosa Technology (乖离率 4.02%) [1] Stocks with Significant Deviation - The stocks with the largest deviation from the annual line include: - Puris: Today's price increased by 7.19% to 30.70 yuan - Aisen Co., Ltd.: Today's price increased by 7.47% to 42.00 yuan - Fosa Technology: Today's price increased by 4.30% to 32.71 yuan [1] Additional Stocks with Positive Performance - Other stocks showing positive performance and their respective deviations include: - Yao Stone Technology: 3.77% increase, 3.51% deviation - Fuling Power: 6.24% increase, 3.42% deviation - Yingjie Electric: 5.37% increase, 3.38% deviation [1] Summary of Stocks with Minor Deviations - Stocks with minor deviations from the annual line include: - Huayang Intelligent: 4.58% increase, 2.48% deviation - Boying Special Welding: 2.32% increase, 2.06% deviation - Stone Technology: 2.02% increase, 1.96% deviation [1]

药石科技（300725）公告，股东吴希罕已完成减持计划，共减持74.38万股，占公司剔除已回购股份后 总股本比例0.37%。减持期间为2025年5月13日至2025年5月20日，减持均价为32.84元/股。此次减持计 划符合相关法律法规及规范性文件的规定，不会导致公司控制权发生变更。 ...